GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexon Inc (NAS:ANNX) » Definitions » Equity-to-Asset

Annexon (Annexon) Equity-to-Asset : 0.84 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Annexon Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Annexon's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $250.56 Mil. Annexon's Total Assets for the quarter that ended in Dec. 2023 was $297.67 Mil.

The historical rank and industry rank for Annexon's Equity-to-Asset or its related term are showing as below:

ANNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.79   Med: 0.83   Max: 0.97
Current: 0.84

During the past 6 years, the highest Equity to Asset Ratio of Annexon was 0.97. The lowest was 0.79. And the median was 0.83.

ANNX's Equity-to-Asset is ranked better than
74.02% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs ANNX: 0.84

Annexon Equity-to-Asset Historical Data

The historical data trend for Annexon's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexon Equity-to-Asset Chart

Annexon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.87 0.97 0.81 0.81 0.84

Annexon Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.80 0.79 0.77 0.84

Competitive Comparison of Annexon's Equity-to-Asset

For the Biotechnology subindustry, Annexon's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annexon's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexon's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Annexon's Equity-to-Asset falls into.



Annexon Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Annexon's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=250.556/297.674
=

Annexon's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=250.556/297.674
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annexon  (NAS:ANNX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Annexon Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Annexon's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Annexon (Annexon) Business Description

Traded in Other Exchanges
N/A
Address
1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Executives
Ted Yednock officer: EVP & Chief Innovation Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Muneer A Satter director C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jennifer Lew officer: EVP & Chief Financial Officer 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michael Overdorf officer: EVP & Chief Business Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Douglas Love director, officer: President & CEO C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Dean Richard Artis officer: EVP & Chief Scientific Officer C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Larry Mattheakis officer: Chief Scientific Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Sanjay Keswani officer: EVP & Chief Medical Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William H. Carson director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016
Clarus Lifesciences Iii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

Annexon (Annexon) Headlines

From GuruFocus

Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-04-2023

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 01-17-2023